-
Subject Areas on Research
-
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
-
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
-
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
-
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
-
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
-
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
-
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
-
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
-
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
-
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
-
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
-
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
-
BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.
-
Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.
-
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
-
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
-
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
-
Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
-
Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?
-
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
-
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
-
Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
-
Clostridium septicum abscess in hepatic metastases: successful medical management.
-
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
-
Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.
-
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
-
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
-
Correlation of intralesional in vivo chemotherapy of line 10 hepatoma with in vitro drug sensitivity.
-
Cyclocreatine in cancer chemotherapy.
-
Cytoprotection by somatostatin of normal and malignant clonogenic cells against the in vitro cytotoxicity of bischloroethylnitrosourea (BCNU).
-
DNA interstrand crosslinking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance.
-
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
-
Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione.
-
Detecting treatment-by-centre interaction in multi-centre clinical trials.
-
Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro.
-
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
-
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
-
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
-
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
-
Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.
-
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
-
Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
-
Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells.
-
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
-
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
-
Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.
-
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
-
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.
-
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.
-
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
-
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
-
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
-
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
-
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
-
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
-
Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
-
Immunobiology of primary intracranial tumors.
-
In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity.
-
In vitro repair synthesis of BCNU-induced DNA damage.
-
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
-
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
-
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
-
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
-
Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it.
-
Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.
-
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
-
Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study).
-
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
-
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).
-
O6-benzylguanine-mediated enhancement of chemotherapy.
-
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
-
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
-
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
-
Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen.
-
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
-
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
-
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
-
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
-
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
-
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
-
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
-
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
-
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
-
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
-
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
-
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.
-
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
-
Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione.
-
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
-
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer.
-
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
-
Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.
-
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
-
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
-
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
-
Stimulation and inhibition of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced strand breaks and interstrand cross-linking in Col E1 plasmid deoxyribonucleic acid by polyamines and inorganic cations.
-
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
-
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
-
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
-
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
-
Therapy of myeloma.
-
Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
-
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
-
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
-
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
-
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
-
Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea.
-
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.
-
Keywords of People
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Yan, Hai,
Adjunct Professor of Pathology,
Pathology